<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>Bootstrap demo</title>
    <link rel="stylesheet" href="CSS/style.css">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.11.3/font/bootstrap-icons.min.css">
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-T3c6CoIi6uLrA9TneNEoa7RxnatzjcDSCmG1MXxSR1GAsXEV/Dwwykc2MPK8M2HN" crossorigin="anonymous">
  </head>
  <body>
    <header>
    <?php include("header.php");?>
    </header>

    <main>
        <section class="serv_content">
          <div class="container">
            <div class="row">
              <div class="col-12">
                 <h2>15.<u>REAL-TIME PCR - MTB/RIF (FOR MDR - TB)/CBNAAT</u></h2>
                 <p>Real-time PCR, also known as quantitative PCR or qPCR, is a revolutionary molecular biology technique that has transformed the way we diagnose and monitor various diseases, including tuberculosis (TB). </p>
                 <p>In particular, real-time PCR plays a critical role in the detection of drug-resistant strains of TB, such as multidrug-resistant TB (MDR-TB). One of the most remarkable advances in this field is the development of the MTB/RIF assay, also known as GeneXpert, which combines real-time PCR with the detection of specific genetic markers associated with Mycobacterium tuberculosis (MTB) and resistance to rifampicin (RIF), a key anti-TB drug. Additionally, the assay's cartridge-based nucleic acid amplification test (CBNAAT) format makes it a game-changer in the fight against MDR-TB.</p>
                 <p>Mycobacterium tuberculosis is the bacterium responsible for TB, a global health threat that affects millions of people. The emergence of drug-resistant strains, such as MDR-TB, poses an even greater challenge to public health systems worldwide. Conventional methods for diagnosing TB and drug resistance, like microscopy and culture, are time-consuming, labor-intensive, and often inadequate for early diagnosis. This is where real-time PCR and the MTB/RIF assay come into play.</p>
                 <p>The MTB/RIF assay is a groundbreaking real-time PCR test that can rapidly detect MTB and identify whether it carries mutations associated with rifampicin resistance. Rifampicin is one of the most potent first-line TB drugs, and resistance to it is often a marker for MDR-TB. What makes this assay so remarkable is its speed and accuracy. It can provide results in as little as two hours, compared to the weeks required by traditional culture-based methods. This rapid turnaround time is crucial for early diagnosis, treatment initiation, and infection control.</p>
                 <p>The assay's real-time PCR component uses specific primers and probes to amplify and detect the DNA of MTB in the patient's sputum sample. Additionally, it targets the rpoB gene, which is associated with rifampicin resistance. By monitoring the amplification of the target DNA in real time, the test can quantify the amount of MTB DNA in the sample and detect mutations in the rpoB gene simultaneously. This dual functionality makes the MTB/RIF assay a powerful tool for diagnosing both TB and MDR-TB.</p>
                 <p>Furthermore, the assay is relatively simple to use, making it suitable for settings with limited laboratory infrastructure. Its cartridge-based design simplifies the workflow, minimizing the risk of contamination and human error. Healthcare providers can load the patient's sputum sample into the cartridge, place it in the GeneXpert instrument, and the machine takes care of the rest. The results are displayed on the instrument's screen, and they are easy to interpret, making it feasible for healthcare workers with varying levels of expertise to use the technology effectively.</p>
                 <p>CBNAAT technology, as part of the MTB/RIF assay, is not only advantageous for its simplicity but also for its ability to directly process the patient's sputum sample without the need for extensive pre-processing steps. This is particularly advantageous in resource-limited settings, where TB is more prevalent and access to sophisticated laboratory equipment is limited.</p>
                 <span>"In summary, real-time PCR in the form of the MTB/RIF assay, with its CBNAAT technology, has revolutionized the diagnosis of TB, especially MDR-TB. It offers rapid and accurate results, which are crucial for early treatment and reducing the spread of drug-resistant strains. The simplicity of the assay's design and the ability to process sputum samples directly makes it a valuable tool for healthcare systems worldwide, and it represents a significant step forward in the global effort to control tuberculosis. By bridging the gap between molecular biology and accessible, on-the-ground testing, this technology is saving lives and contributing to the fight against one of the world's most persistent infectious diseases."</span>
              </div>
            </div>
          </div> 
          <div class="container py-5">
            <div class="row">
                <div class="col-md-12 d-flex justify-content-center align-items-center">
                  <button><a href="contact.php">Know More</a></button>
                </div>
            </div>
          </div>
        </section>
    </main>

    <footer>
        <?php include("footer.php");?>
    </footer>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-C6RzsynM9kWDrMNeT87bh95OGNyZPhcTNXj1NW7RuBCsyN/o0jlpcV8Qyq46cDfL" crossorigin="anonymous"></script>
  </body>
</html>